Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

PURPOSE: In patients with epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer (NSCLC), EGFR tyrosine kinase inhibitors (TKIs) improve response rate and survival. However, most patients eventually develop resistance. This study aimed to identify the role of CD73 in EGFR-mutant N...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Miso, Kim, Soyeon, Yim, Jeemin, Keam, Bhumsuk, Kim, Tae Min, Jeon, Yoon Kyung, Kim, Dong-Wan, Heo, Dae Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582532/
https://www.ncbi.nlm.nih.gov/pubmed/37218137
http://dx.doi.org/10.4143/crt.2023.311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582532/
https://www.ncbi.nlm.nih.gov/pubmed/37218137
http://dx.doi.org/10.4143/crt.2023.311

Ejemplares similares